change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
http://www.marketwatch.com/story/aradigm-selects-pulmaquintm-for-phase-3-development-and-announces-issuance-of-its-first-us-patent-covering-inhaled-ciprofloxacin-formulations-2011-12-07?reflink=MW_news_stmp
Insiders Acquired More Shares Again!
http://investor.aradigm.com/secfiling.cfm?filingid=1209191-11-48507
http://investor.aradigm.com/secfiling.cfm?filingid=1209191-11-48503
ARDM should get FDA approval for PHASE III (LIPOQUIN™, LIPOQIN™, PULMAQUIN™, PULMAQIN™) very soon. I expect it by the end of the 3Q 2011. And, ARDM will announce partnering with one or more pharma firms after/before FDA approval...
I expect the price will shoot UP out of this triangle ;)
...and price above $3 after NDA & FDA in 2012.
More and more royalties for ARDM
http://www.marketwatch.com/story/zogenix-and-durect-announce-development-and-license-agreement-for-antipsychotic-product-candidate-2011-07-12?reflink=MW_news_stmp
...In August 2006, Aradigm sold all of its assets related to the needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix.
Aradigm is entitled to royalties from the sale of all products based on this technology platform.
http://investor.aradigm.com/releasedetail.cfm?releaseid=542968
Aradigm Announces Private Placement for $4.75 Million
http://www.businesswire.com/news/home/20110706005458/en/Aradigm-Announces-Private-Placement-4.75-Million
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=589267
Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it has entered into an $8.5 million royalty financing agreement (the "Transaction") with a syndicate of lenders arranged by PBS Capital Management LLC ("PBS Capital"). The agreement created a debt obligation (the "Term Loan") that will be repaid through and secured by royalties from net sales of the SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system payable to Aradigm under its Asset Purchase Agreement ("APA") with Zogenix, Inc. ("Zogenix"). The APA provides for Aradigm to receive 3% royalty on net sales of SUMAVEL DosePro in all territories.
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=586668
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=585430
Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month
SUMAVEL® DosePro® Provides Treatment Option for Migraine Patients; Addresses 50% of Oral Triptan Users who are Dissatisfied with their Current Migraine Therapy
http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=1571025&highlight=
Aradigm is entitled to 3% royalty on net sales of SUMAVEL DosePro in all territories until Jan, 2020.
Aradigm Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation in Bronchiectasis
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=582801
Aradigm will release results from the ORBIT-1 Phase 2b study
in non-cystic fibrosis bronchiectasis by the end of the month.
I believe in positive result again - all endpoints will meets at 99,99 % again.
LifeSci Advisors Announces Investment Opinion on Aradigm Corporation
http://www.lifesciadvisors.com/clientinfo/aradigm/ARDM_LSA_Initiation_2-17-11.pdf
NEW FORM 4
Insider Acquired More Shares And Stock Options (right to buy).
http://www.sec.gov/Archives/edgar/data/1218821/000120919111032107/xslF345/doc4.xml
Insiders Acquired More Shares And Stock Options (right to buy)
Three Insiders Acquired 276 316 Shares And Stock Options (right to buy) 300 000 Shares At $0,19.
http://www.sec.gov/Archives/edgar/data/1202286/000120919111031993/xslF345/doc4.xml
http://www.sec.gov/Archives/edgar/data/1190558/000120919111031994/xslF345/doc4.xml
http://www.sec.gov/Archives/edgar/data/1230807/000120919111031995/xslF345/doc4.xml
The result from the ORBIT-1 Phase 2b study
in non-cystic fibrosis bronchiectasis later in the second quarter of 2011.
I believe in positive result again - all endpoints will meets again at 99,99 %.
CHANGES ON XETRA - WMI (ISIN US9393221034)
The trading model type will change from one auction to continuous trading.
The changes of the trading models type will be implemented in the time from friday to monday.
Bankrupt bank to become giant tax break
http://www.marketwatch.com/story/bankrupt-bank-to-become-giant-tax-break-2011-05-24?reflink=MW_news_stmp
Do not panic! The Elliott wave #3 ($0.17) was yesterday. The Elliott wave #4 (cca $0,094 = cca EUR 0,068) will be now. Than should go UP again. My recomendation is BUY, the best at $0,094.
WMI (ISIN US9393221034)
AVAX Technologies, Inc. Files Amendment No. 1 to Form 10 on May 5, 2011
http://www.sec.gov/Archives/edgar/data/1015441/000114420411026242/v219857_10-12ga.htm
LIPOQUIN™ and PULMAQUIN™ - Aradigm Corp. Should Sign Contracts With One Or More Partners This Year.
"We have started discussions with more partners long time ago. It is realistic we will sign contracts with one or more partners this year." Said CEO Igor Gonda yesterday.
The realistic price (with signed contracts) is in the range $3,20 - $3,60. Close Yesterday $0,165.
The Annual Meeting of Shareholders of Aradigm Corporation, a California corporation (“Aradigm”) will be held on Thursday, May 26, 2011, at 9:00 a.m. local time at Aradigm’s office. The most important could be purpose - item 3).
http://www.sec.gov/Archives/edgar/data/1013238/000095012311031892/f58789dedef14a.htm
LIPOQUIN™, LIPOQIN™, PULMAQUIN™, PULMAQIN™
The Company received Notices of Allowance from the U.S. Patent and Trademark Office for the Company's trademark applications for LIPOQUIN™ (LIPOQIN™) and PULMAQUIN™ (PULMAQIN™) to be used as marks for ARD-3100 and ARD-3150, respectively.
http://www.trademarkia.com/correspondent-harold-milstein-1-414641
The results from the ORBIT-1 Phase 2b study in non-cystic fibrosis bronchiectasis later in the second quarter of 2011.
Royalties for Aradigm Corp. (ARDM) for the 1Q 2011
Aradigm is entitled to 3% royalty on net sales of SUMAVEL DosePro in all territories, including the US where this product is marketed by Zogenix and Astellas Pharma US, Inc.
Zogenix, Inc. (Nasdaq:ZGNX) will release financial results for the first quarter ended March 31, 2011 after market close on Monday, May 16, 2011 at 4:00 p.m. ET ( 1:00 p.m. PT ) and hold a conference call the same day at 4:30 p.m. ET ( 1:30 p.m. PT ) to discuss these financial results.
$3.5B Market Acute Migraines and Cluster Headaches
Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference on Wednesday, May 4, 2011 at 11:30 am local time. The conference is being held in Berlin, Germany.
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=573894
Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks
http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=1549823&highlight=
Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program
http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=1549270&highlight=
Aradigm is entitled to 3% royalty on net sales of SUMAVEL DosePro in all territories until Jan, 2020.
$3.5B Market Acute Migraines and Cluster Headaches
RW for AVAX TECHNOLOGIES INC
http://www.sec.gov/Archives/edgar/data/1015441/000114420411019964/v216782_rw.htm
Aradigm Will Complete Results From Phase 2b Study
of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis By The End Of The Month.
Results Will Refine Protocols for Pivotal Phase 3 Trial Design.
http://www.businesswire.com/news/home/20110322005689/en/Aradigm-Completes-Enrollment-Phase-2b-Study-Inhaled
DEF 14A for ARADIGM CORP (definitive proxy statement)
http://www.sec.gov/Archives/edgar/data/1013238/000095012311031892/f58789dedef14a.htm
Aradigm Wants Start Phase 3 CFI ARD-3100(ARD-3150) This Year.
Liposomal Ciprofloxacin for Inhalation has Unrecognized Potential. Aradigm is developing a potential best-in-class inhaled antibiotic – a liposomal formulation of ciprofloxacin for inhalation (CFI, ARD-3100) and a secondgeneration formulation, dual release CFI (DRCFI, ARD-3150) to treat bacterial infections in the lungs associated with cystic fibrosis (CF) and bronchiectasis (BE). The unique liposomal formulation improves the pharmacokinetic profile to once daily (QD) versus BID and TID for TOBI (tobramycin) and Cayston (aztreonam). More importantly, the liposomal formulation reduces adverse lung reactions such as bronchospasm that have historically handicapped the development of inhaled antibiotics outside of CF. We do not believe investors have recognized the unique attributes of ARD-3100/3150 (CFI/DRCFI) and the implications for utility outside of CF.
(source LIFESCI ADVISORS)
LifeSci Advisors Announces Investment Opinion on Aradigm Corporation
LifeSci Advisors Announces Investment Opinion on Aradigm Corporation
http://www.lifesciadvisors.com/clientinfo/aradigm/ARDM_LSA_Initiation_2-17-11.pdf
Aradigm Announces Fourth Quarter 2010 and Full Year Financial Results
Net Loss is Reduced by 61% While Advancing Bronchiectasis Clinical Studies
http://www.businesswire.com/news/home/20110324005419/en/Aradigm-Announces-Fourth-Quarter-2010-Full-Year
Succesfull partnering...
Several companies interested in Aradigm's products. Said CEO Igor Gonda at Roth Capital Partners March 15, 2011.
Who is it? GlaxoSmithKline plc (GSK), Novo Nordisk A/S (NVO), Zogenix, Inc. (ZGNX) or ...?
Aradigm should unveil succesfull partnering soon!
Four Quarter and Full Year 2010 Financial Results By The End Of March 2011
Aradigm Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis.
Results Will Refine Protocols for Pivotal Phase 3 Trial Design.
http://ih.advfn.com/p.php?pid=nmona&article=46969489&symbol=ARDM
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=559210
Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years.
Newly Issued Patent Covers Product Until 2025.
http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=1539722&highlight=
http://www.thestreet.com/story/11047268/1/zogenix-announces-extension-of-sumavelr-doseprotm-us-patent-protection-by-eight-years.html
http://www.sec.gov/Archives/edgar/data/1375151/000119312511067892/d8k.htm
Aradigm to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Igor Gonda, PhD., Aradigm's President and CEO, will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 4:00 pm Pacific time. The conference is being held at the Ritz Carlton Laguna Niguel.
Attendance at the conference is by invitation only. A live webcast of the presentation will be available at www.aradigm.com and a webcast replay will be archived on the Company's website for 60 days.
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=555947
Aradigm Should Unveil Partnering With Four Quarter and Full Year 2010 Financial Results By The End Of March 2011 (Form 10-Q and Form 8-K).
More than double royalties for Aradigm in 2011
Zogenix Reports Fourth Quarter and Full Year 2010 Financial Results
Net product revenue on sales of SUMAVEL DosePro for the fourth quarter 2010 was $7.2 million, up 27% from $5.7 million in the third quarter 2010. Net product revenue for the full-year was $19.1 million, consisting of $18.7 million in SUMAVEL DosePro prescriptions dispensed to patients in the U.S. and $0.4 million in sales to Zogenix’s E.U. commercialization partner Desitin.
2011 Financial Guidance
For the full-year 2011, the Company anticipates total revenue in the range of $46 million to $52 million which includes $6 million of contract revenue from the Astellas co-promotion agreement.
http://www.sec.gov/Archives/edgar/data/1375151/000119312511055024/dex991.htm
More than double royalties for Aradigm in 2011 = cca $1.2 million to $1.38 million!!!
Thursday, March 3, 2011, 11:50 - 12:30 AM - Aradigm Corporation (ARDM) Presents at Pharma & Biotech Licensing & Partnering.
http://www.iibig.com/conferences/P1101/overview.html
Thursday, March 3, 2011 at 4:30 p.m. ET - Zogenix To Hold Conference Call To Discuss Fourth Quarter And Full Year 2010 Financial Results
SAN DIEGO, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the fourth quarter and full year ended December 31, 2010 after market close on Thursday, March 3, 2011 at 4:30 p.m. ET (1:30 p.m. PT) and hold a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for the fourth quarter and full year ended December 31, 2010.
Zogenix's first commercial product, SUMAVEL ® DosePro™ ( sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache.
$3.5B Market Acute Migraines and Cluster Headaches
http://www.sec.gov/Archives/edgar/data/1375151/000119312511004298/dex991.htm
In August 2006, Aradigm sold all of its assets related to the needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix. Aradigm is entitled to royalties from the sale of all products based on this technology platform.
Aradigm is entitled to 3% royalty (until January, 2020) on net sales of SUMAVEL ® DosePro™ in all territories, including the US where this product is marketed by Zogenix and Astellas Pharma US, Inc.
http://investor.aradigm.com/releasedetail.cfm?releaseid=542968